Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Utah Medical Products (UTMD) EBIT Margin (2016 - 2025)

Utah Medical Products (UTMD) has 16 years of EBIT Margin data on record, last reported at 26.62% in Q3 2025.

  • For Q3 2025, EBIT Margin fell 679.0% year-over-year to 26.62%; the TTM value through Sep 2025 reached 30.78%, up 3038.0%, while the annual FY2024 figure was 33.23%, 2856.0% up from the prior year.
  • EBIT Margin reached 26.62% in Q3 2025 per UTMD's latest filing, down from 32.11% in the prior quarter.
  • Across five years, EBIT Margin topped out at 40.55% in Q3 2021 and bottomed at 89.13% in Q4 2022.
  • Average EBIT Margin over 5 years is 22.05%, with a median of 34.24% recorded in 2024.
  • Peak YoY movement for EBIT Margin: plummeted -12886bps in 2022, then soared 11703bps in 2024.
  • A 5-year view of EBIT Margin shows it stood at 39.72% in 2021, then plummeted by -324bps to 89.13% in 2022, then rose by 5bps to 85.03% in 2023, then skyrocketed by 138bps to 31.99% in 2024, then fell by -17bps to 26.62% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 26.62% in Q3 2025, 32.11% in Q2 2025, and 32.47% in Q1 2025.